Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Blockchain Moon Acquisition Corp.BMAQ · Entity 123628 | Director | September 14, 2022 | September 21, 2022 |
| Entia Biosciences, Inc.ERGO · Entity 178755 | Director · President and CEO | February 14, 2017 | February 16, 2017 |
| Prestige Consumer Healthcare Inc.PBH · Entity 4350 | Director | July 31, 2018 | August 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Blockchain Moon Acquisition Corp.
Report date September 14, 2022 · Filed September 21, 2022
This filing explicitly reported no securities owned.
Entia Biosciences, Inc.
Report date February 14, 2017 · Filed February 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 850,000 |
Ending reported balance
After 2017-02-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-02-14 · Grant · Acquired 300,000 · Balance 300,000 Row 2 · 2017-02-14 · Grant · Acquired 300,000 · Balance 600,000 Row 3 · 2017-02-16 · Grant · Acquired 250,000 · Balance 850,000 |
Prestige Consumer Healthcare Inc.
Report date July 31, 2018 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 14,598 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Grant · Acquired 3,779 · Balance 14,598 F1: The Reporting Person received 3,779 restricted stock units (equal to $135,000 divided by the closing stock price of $35.73 on July 31, 2018) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received 3,779 restricted stock units (equal to $135,000 divided by the closing stock price of $35.73 on July 31, 2018) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2018 Filed Aug 1, 2018 20:01 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 3,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-041350 · tv499903_4.xml · nonDerivative · entry 1 JOHNSON CARL J · CIK 0001243248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,598 F1 · shares: The Reporting Person received 3,779 restricted stock units (equal to $135,000 divided by the closing stock price of $35.73 on July 31, 2018) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 19:31 UTC | Prestige Consumer Healthcare Inc. PBH · Entity 4350 | GrantCommon Stock, par value $0.01 per share | 2,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-040283 · v472277_4.xml · nonDerivative · entry 1 JOHNSON CARL J · CIK 0001243248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,819 F1 · shares: The Reporting Person received 2,564 restricted stock units (equal to $135,000 divided by the closing stock price of $52.64 on August 1, 2017) in connection with the Issuer's director compensation arrangement. The restricted stock units vest immediately upon execution and acceptance of the award and shall be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of the Reporting Person's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the Reporting Person's Board membership ceases for reasons other than death or disability. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 17:57 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000388 · form4-johnson021617.xml · nonDerivative · entry 3 JOHNSON CARL J · CIK 0001243248 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:57 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000388 · form4-johnson021617.xml · nonDerivative · entry 2 JOHNSON CARL J · CIK 0001243248 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 17:57 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000388 · form4-johnson021617.xml · nonDerivative · entry 1 JOHNSON CARL J · CIK 0001243248 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.